Commvault Systems Inc vs Tempus AI — how do they compare? Commvault Systems Inc trades at $151.43 (market cap $6.25B), while Tempus AI trades at $70.3 (market cap $12.58B). The key difference: Tempus AI is far larger — about 2× Commvault Systems Inc's market cap, and Commvault Systems Inc is trading nearer its 52-week high, Tempus AI nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Commvault Systems Inc for 17 Days and Tempus AI for 22 Days on average.
| CVLT | TEM | |
|---|---|---|
Market Cap | $6.25B | $12.58B |
Volume | 632,727 | 7,444,569 |
Sector | Technology | Broad Market / Factor |
52-Week High | $176.52 | $99.28 |
52-Week Low | $75.18 | $41.55 |
Typical Hold Time | 17 Days | 22 Days |
Enterprise Value | $6.24B | $13.21B |
Signals from Pluang's Aura AI — not financial advice
Commvault Systems (CVLT) trades at $150.28, down 3.03% on the day, but maintains a bullish technical outlook with strong institutional support. The company shows robust revenue growth, with 2026 projections reaching $1.2 billion, though net income margins are expected to compress. Recent positive developments include AWS competency achievements and new board appointments, while analyst consensus remains strongly bullish with a $156.55 price target.
CVLT presents a compelling growth story with consistent earnings beats and expanding enterprise partnerships, but faces valuation concerns with elevated P/E and P/B ratios. The stock's upside potential is supported by strong institutional buying and positive technical momentum, though investors should monitor margin pressures and competitive threats in the data resilience space.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite recent weakness. The company reported Q2 2026 revenue growth of 22% year-over-year and beat EPS estimates for three consecutive quarters, though it remains unprofitable with a net income margin of -17.77%. Recent positive developments include FDA clearance for its ECG-MR AI product and expanded data licensing agreements, fueling investor optimism in the healthtech sector.
The investment outlook is cautiously optimistic, driven by strong analyst support (64% buy ratings) and a consensus price target of $72.60, implying modest upside. Key opportunities include accelerating adoption of AI-powered diagnostics and strategic acquisitions, but risks persist from persistent cash burn, insider selling, and intense competition in the precision medicine space.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.
Read more on CVLT →Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →